Bristol-Myers Squibb Company (BMY)

FairStock Score: 82/100 — HIGH CONVICTION

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style bargain hunt with a Buffett lens on business quality. Bristol-Myers Squibb sells biopharmaceutical medicines in oncology, hematology, immunology, cardiovascular, and neuroscience, with products such as Opdivo, Orencia, and Yervoy. The reported numbers show a real rebound. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $13.0B and net income was $3.3B, or $1.62 diluted EPS, against $12.3B revenue, $1.3B net income, and $0.64 EPS in fiscal Q2 2025, the quarter ended 2025-06-30. For FY2025, ended 2025-12-31, revenue was $48.2B and net income was $7.1B, after FY2024, ended 2024-12-31, produced a net loss of $8.9B. That pattern fits FairStock's computed Lynch category: TURNAROUND—returned to profit after a loss within the last three years. At $56.67 on 2026-10-13, FairStock calculates a P/E of 12.48, FCF yield of 9.9%, PEG of 0.08, and dividend yield of 4.00%. The Piotroski F-Score is 9/9, ROE is 46.60%, and ROCE is 10.72%, but Altman Z of 1.82 and D/E of 2.02 show leverage and balance-sheet risk. The Graham Number is $33.41, so the price is about 69.62% above that asset-based reference. Revenue growth is modest—FY2025 revenue of $48.2B was slightly below FY2024's $48.3B—so the profit surge may not be a straight line. I see a cash-generative turnaround with a modest valuation, but not a classic Graham margin-of-safety bargain.

In plain English: Bristol-Myers Squibb makes and sells medicines for cancer, immune diseases, heart conditions, and brain conditions. The business looks stronger than a few years ago: in the quarter ended 2026-06-30, sales were $13.0 billion and profit was $3.3 billion, while the full fiscal year 2024, ended 2024-12-31, had a large loss. The share price looks low compared with current profits and cash flow, but the company carries a lot of debt and the price is well above one strict accounting-value estimate.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer